Patents by Inventor Hans-Peter Nestler
Hans-Peter Nestler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002374Abstract: The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.Type: ApplicationFiled: May 11, 2022Publication date: January 4, 2024Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Sylvie Baltzer, Bertrand Vivet, Brian Freed, Hans Peter Nestler, Helen Yeoman, Ingrid Mechin, Martin Smrcina, Nina Ma, Sylvain Lebreton, Ryan Hartung, William Wire, Sukanthini Thurairatnam
-
Publication number: 20230159439Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.Type: ApplicationFiled: June 3, 2022Publication date: May 25, 2023Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Ingrid Mechin, Joseph Kim, Martin Smrcina, Nina Ma, Ronghua Li, Ryan Hartung, William Bock, Bertrand Vivet
-
Publication number: 20230159438Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.Type: ApplicationFiled: June 3, 2022Publication date: May 25, 2023Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Helen Yeoman, Martin Smrcina, Ronghua Li, Ryan Hartung, William Wire, Bertrand Vivet, Nina Ma
-
Publication number: 20230147360Abstract: The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.Type: ApplicationFiled: June 3, 2022Publication date: May 11, 2023Inventors: Junkai Liao, Mark Munson, Zhongli Gao, Gregory Hurlbut, Hans Peter Nestler, Ingrid Mechin, Martin Smrcina, Ronghua Li, Ryan Hartung, William Bock, Bertrand Vivet, Andrew Scholte
-
Patent number: 9540391Abstract: The present invention relates to compounds of the formula (I), wherein R1, R11, R12 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, inflammation or could show beneficial effects in pain, dyslipidemia and atherosclerosis. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: January 16, 2014Date of Patent: January 10, 2017Assignee: SANOFIInventors: Katrin Lorenz, Kristin Breitschopf, Hartmut Strobel, Maria Mendez-Perez, Li-hsing Wang, Alexander Schiffer, Joseph T. Kim, Hans-Peter Nestler, Mark Drew
-
Publication number: 20150336979Abstract: The present invention relates to compounds of the formula (I), wherein R1, R11, R12 and X have the meanings indicated in the claims. The compounds of formula I are valuable pharmacologically active compounds. They are highly potent and selective soluble epoxide hydrolase inhibitors and are suitable, for example, for the therapy and prophylaxis of renal failure, diabetic nephropathy, type 2 diabetes mellitus, inflammation or could show beneficial effects in pain, dyslipidemia and atherosclerosis. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: January 16, 2014Publication date: November 26, 2015Inventors: Katrin LORENZ, Kristin BREITSCHOPF, Hartmut STROBEL, Maria MENDEZ-PEREZ, Li-hsing WANG, Alexander SCHIFFER, Joseph T. KIM, Hans-Peter NESTLER, Mark DREW
-
Patent number: 7435747Abstract: The present invention relates to compounds of the formula I, in which R0; Q; X; Q?, D, R10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: July 7, 2004Date of Patent: October 14, 2008Assignee: Sanofi-Aventis Deutschland GmbHInventors: Anuschirwan Peyman, David William Will, Uwe Gerlach, Marc Nazaré, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
-
Patent number: 7153876Abstract: Compounds of formula I, in which R1, R2, A, and B having the definitions set forth in the claims, are valuable pharmacologically active compounds, which exhibit a strong antithrombotic effect and are suitable, for example, for treating thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. Also disclosed are processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: August 6, 2003Date of Patent: December 26, 2006Assignee: Sanofi-Aventis Deutschland GmbHInventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder
-
Publication number: 20050143419Abstract: The present invention relates to compounds of the formula I, in which R0; Q; X; Q?, D, R10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: July 7, 2004Publication date: June 30, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Anuschirwan Peyman, David Will, Uwe Gerlach, Marc Nazare, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
-
Publication number: 20040137543Abstract: It is intended to provide novel lipopolysaccharide adsorbents (bacteriotoxin adsorbents) which can be easily synthesized and modified into various analogous structures and are usable in adsorbing various lipopolysaccharides and a method of screening the same. A method of screening a bacteriotoxin adsorbent characterized by performing a binding assay with a peptide library with the use of a lipid A radioisotope-labeled preparation wherein a radioisotope has been introduced into a phosphonoxyethyl derivative of biosynthetic precursor type lipid A or Escherichia coli type lipid A; and bacteriotoxin adsorbents comprising a specific peptide library which are found out by the above screening method.Type: ApplicationFiled: October 17, 2003Publication date: July 15, 2004Inventors: Koichi Fukase, Hans Peter Nestler
-
Patent number: 6743790Abstract: The present invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5, R6, A, X, m and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, for example as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: June 6, 2001Date of Patent: June 1, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Otmar Klingler, Manfred Schudok, Hans-Peter Nestler, Hans Matter, Herman Schreuder
-
Patent number: 6706715Abstract: The present invention relates to compounds of the formula I, in which R1, R2, R4, R5, D1, D2, X1, X2, X3, A and B have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: June 26, 2002Date of Patent: March 16, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder, Hauke Szillat
-
Publication number: 20040034027Abstract: Compounds of formula I, 1Type: ApplicationFiled: August 6, 2003Publication date: February 19, 2004Applicant: Aventis Pharma Deutschland GmbHInventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder
-
Patent number: 6645992Abstract: Compounds of formula I, in which R1, R2, A, and B having the definitions set forth in the claims, are valuable pharmacologically active compounds, which exhibit a strong antithrombotic effect and are suitable, for example, for treating thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. Also disclosed are processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: October 1, 2001Date of Patent: November 11, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder
-
Publication number: 20030176439Abstract: The present invention relates to compounds of the formula I, 1Type: ApplicationFiled: June 26, 2002Publication date: September 18, 2003Applicant: Aventis Pharma Dutschland GmbHInventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder, Hauke Szillat
-
Publication number: 20030027828Abstract: Compounds of formula I, 1Type: ApplicationFiled: October 1, 2001Publication date: February 6, 2003Inventors: Manfred Schudok, Otmar Klingler, Hans-Peter Nestler, Hans Matter, Herman Schreuder
-
Publication number: 20020173656Abstract: The present invention relates to compounds of the formula I, 1Type: ApplicationFiled: December 6, 2001Publication date: November 21, 2002Inventors: Anuschirwan Peyman, David William Will, Uwe Gerlach, Marc Nazare, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
-
Publication number: 20020052417Abstract: The present invention relates to compounds of the formula I, 1Type: ApplicationFiled: June 6, 2001Publication date: May 2, 2002Inventors: Otmar Klingler, Manfred Schudok, Hans-Peter Nestler, Hans Matter, Herman Schreuder